Biogen Inc. has filed an 8-K report detailing an expected charge of approximately $34 million related to acquired in-process research and development expenses for the first quarter of 2026. This charge is anticipated to affect both GAAP and non-GAAP net income per diluted share by approximately $0.19. The company clarified that these expenses arise from collaboration and license agreements, including upfront and milestone payments, as well as potential premiums on equity securities and asset acquisitions. Biogen has not provided forecasts for future expenses of this nature due to the inherent uncertainties surrounding the timing and magnitude of such transactions. The results for the quarter ending March 31, 2026, are still subject to finalization and may differ from the preliminary estimates provided in this filing. Investors are advised to consider the potential impact of this charge on the company's financial performance, as it may lead to a slight negative effect on stock price in the short term.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.